IIROC Trading Halt – ROVR

Canada NewsWire

VANCOUVER, BC, Dec. 7, 2020 /CNW/ – The following issues have been halted by IIROC:

Company: Rover Metals Corp.

TSX-Venture Symbol: ROVR

All Issues: Yes

Reason: At the Request of the Company Pending News

Halt Time (ET): 7:54 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Marinus Pharmaceuticals Provides Additional Ganaxolone Data During Scientific Exhibit at AES2020 Virtual Annual Meeting and Provides Corporate Update

Marinus Pharmaceuticals Provides Additional Ganaxolone Data During Scientific Exhibit at AES2020 Virtual Annual Meeting and Provides Corporate Update

  • Top-line data from the Marigold Study in CDKL5 deficiency disorder (CDD) presented as late breaking results during AES scientific sessions; An analysis of data from the Marigold Study shows a consistent efficacy signal across multiple subgroups, including a 36.7% estimated difference in major motor seizure frequency relative to placebo in U.S. patients (n=41)
  • Preliminary analysis of the Marigold Study open label extension provides supportive data on the durability of ganaxolone efficacy data, including a 52.7% median major motor seizure frequency reduction in patients who have completed approximately one year of therapy

  • Higher average ganaxolone plasma concentrations correlated with improved seizure frequency reductions in CDD patients. Findings support three times a day dosing as utilized in the Marigold Study and studies in other chronic epilepsy indications, as well as future oral formulation development designed to improve ganaxolone exposure levels
  • Two case studies on pediatric super-refractory status epilepticus (SRSE) are the first published abstracts on the use of IV ganaxolone in treating SRSE
  • Marinus also announces an expanded access program (EAP) for U.S. patients with CDD, making ganaxolone available to patients under a treatment IND

RADNOR, Pa.–(BUSINESS WIRE)–Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it will host a virtual Scientific Exhibit at the American Epilepsy Society (AES) Annual Meeting (AES2020) from 8:00 AM to 11:00 AM Eastern Time today. At the Scientific Exhibit, Marinus will have 10 posters highlighting the company’s clinical development programs in treating CDKL5 deficiency disorder (CDD) and refractory status epilepticus (RSE).

“We are excited to share the important insights and data we have compiled for this year’s AES meeting, with four scientific posters, two of which were accepted as late breaking results – one in CDD and another in RSE. We will also highlight key data from the Marigold Study during our Scientific Exhibit, with analyses on patient subsets, preliminary durability of effect in the open label portion of the trial, and on the PK/PD profile of ganaxolone,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We also look forward to discussing these data further at our AES Virtual Investor Event later today.”

Highlights from new analyses in the Phase 3 Marigold Study of ganaxolone in CDD presented during the Scientific Exhibit include the following:

“Effect of Ganaxolone on Seizure Frequency Across Subpopulations of Patients with CDKL5 Deficiency Disorder: Subgroup Analyses of the Marigold Study,” by E. M. Pestana-Knight, et al.

An analysis of data from the Marigold Study showed patients on ganaxolone consistently demonstrated numerical improvements in the change in major motor seizure frequency relative to placebo across the following subgroups: age, gender, baseline seizure frequency, number of concomitant antiepileptic drugs, geography and baseline allopregnanolone sulfate levels. These findings support ganaxolone’s effect across the broad CDD population studied. Data collected in patients enrolled in the United States (n=41) showed a stronger effect with a 36.7% estimated difference in major motor seizure frequency relative to placebo.

“Pharmacokinetic-Pharmacodynamic Analysis in Ganaxolone-Treated Patients with CDKL5 Deficiency Disorder: Results From the Marigold Study,” by J. Hulihan, et al.

Higher plasma ganaxolone concentrations were correlated with greater reductions in major motor seizure frequency. However, no differences in the rates of relevant adverse events were noted across ganaxolone plasma concentration groups. These findings highlight the importance of achieving adequate plasma ganaxolone concentrations and suggest that three times a day (TID) dosing has the potential to increase trough ganaxolone levels and may provide improved seizure control. In addition, this analysis supports efforts to develop new oral ganaxolone formulations that aim to improve pharmacokinetic properties to better achieve target ganaxolone exposure levels.

“Extended Duration Safety and Efficacy of Ganaxolone for the Treatment of CDKL5 Deficiency Disorder: Preliminary Open-Label Extension Analysis (Marigold Study),” by N. Specchio, et al.

Preliminary data from patients in the open-label extension phase of the Marigold Study as of September 2020 were summarized. Patients on ganaxolone in the double-blind phase continued to experience a maintained improvement in major motor seizure frequency through eight months in the open-label extension, representing approximately 12 months in total on ganaxolone. This group of patients treated with ganaxolone for 12 months (n=17) experienced a median 52.7% reduction in major motor seizure frequency relative to baseline.

Patients on placebo in the double-blind phase showed improvements in major motor seizure frequency when transitioning to open label ganaxolone. These preliminary findings suggest that ganaxolone has the potential to provide clinically meaningful, durable seizure improvements in patients with CDD.

The following posters were presented during the AES Scientific Sessions:

For full list of posters presented, please visit the Marinus Website Poster Page.

Corporate Update:

Status Epilepticus

Marinus is currently recruiting patients in RSE in its Phase 3 RAISE clinical trial. In addition, the company is planning a clinical trial of ganaxolone in Established Status Epilepticus (ESE) in patients presenting to emergency rooms, with a projected trial initiation in 2H 2021. Marinus also intends to continue making ganaxolone available to clinicians who request the drug for treatment of super refractory status epilepticus on a case-by-case basis under emergency IND treatment.

Expanded access program (EAP) in CDD makes ganaxolone broadly available to patients

During AES2020, Marinus announced the launch of an expanded access program (EAP) that will allow the company to offer ganaxolone to U.S. patients with CDD, including children at least two years of age, who were unable to participate in the company’s Phase 3 Marigold Study. This will provide patients with CDD access to ganaxolone under a treatment IND.

CDD Regulatory Plans

Marinus is preparing to meet with the FDA in Q1 2021 in connection with its planned mid-2021 NDA submission for CDD, with a 1H 2021 pre-marketing authorization application (MAA) meeting with the European Medicines Agency (EMA).

Investor Meeting Today

Marinus to Host Virtual Investor Event at AES today from 12:00 PM – 2:00 PM Eastern Time. To register in advance and listen to the live webinar please click on http://wsw.com/webcast/cc/mrns.

About Ganaxolone

Ganaxolone, a positive allosteric modulator of GABAA receptors, is being developed in intravenous and oral formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Unlike benzodiazepines, ganaxolone exhibits antiseizure, antidepressant and anti-anxiety activity via its effects on synaptic and extrasynaptic GABAA receptors. More than 1,600 study participants, both adults and children, have received ganaxolone at therapeutically relevant dose levels and treatment regimens for up to four years.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 2 trial in tuberous sclerosis complex, as well as a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy. The company is initiating a Phase 3 trial in status epilepticus. For more information visit www.marinuspharma.com.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “believe,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding: our plans to initiate a clinical trial of ganaxolone in ESE in the second half of 2021; our expectations to meet with the FDA regarding our NDA for ganaxolone for the treatment of CDD in the first quarter of 2021; our expectation to submit an NDA for ganaxolone for the treatment of CDD in mid-2021; our expectation to have a pre-MAA meeting with the EMA in the first half of 2021; our clinical development plans for ganaxolone; and for the safety and efficacy of ganaxolone. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; clinical trial results may not support further development in a specified indication or at all; actions or advice of the U.S. Food and Drug Administration may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; our ability to obtain and maintain regulatory approval for our product candidate; delays, interruptions or failures in the manufacture and supply of our product candidate; our ability to raise additional capital; the effect of the COVID-19 pandemic on our business, the medical community and the global economy; and the availability or potential availability of alternative products or treatments for conditions targeted by us that could affect the availability or commercial potential of our product candidate. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.

Sasha Damouni Ellis

Vice President, Investor Relations & Corporate Communications

Marinus Pharmaceuticals, Inc.

484-253-6792

[email protected]

KEYWORDS: Europe United States North America Pennsylvania Washington

INDUSTRY KEYWORDS: Other Health Research General Health Pharmaceutical Consumer Children Clinical Trials Science Biotechnology FDA Other Science Health

MEDIA:

Logo
Logo

All-New Arlo Essential Video Doorbell Wire-Free Now Available

Industry-Leading 180-Degree Field-of-View with Square 1:1 Aspect Ratio Delivers Most Complete Front-Entry Protection, With Direct-to-Mobile Video Calls for Faster Response

PR Newswire

SAN JOSE, Calif., Dec. 7, 2020 /PRNewswire/ — Arlo Technologies, Inc. (NYSE: ARLO), a leading internet-connected camera brand, today announced the availability of its all-new Arlo Essential Video Doorbell Wire-Free. The latest offering brings the award-winning features of the popular Arlo Wired Video Doorbell to an easy-to-install, wire-free, battery-powered design. An industry-leading, 180-degree viewing angle with a square, 1:1 aspect ratio ensures users can see packages on the ground or visitors from head-to-toe on their mobile devices. HD video resolution combined with direct-to-mobile video calls, clear, two-way audio and personalized alerts, allow users to quickly reply to guests or take action. Able to connect directly to WiFi, the latest solution can be powered by its rechargeable battery1 or hardwired for continuous charging2. The Arlo Essential Video Doorbell Wire-Free is available now at BestBuy.com, Amazon.com and Arlo.com for an MSRP of $199.99.

“Smart video doorbells are a vital component of home security, especially heading into the holiday season when deliveries are more prevalent,” said Tejas Shah, SVP of Product and CIO at Arlo. “The new Essential Video Doorbell Wire-Free provides comprehensive monitoring thanks to industry-leading picture and audio quality combined with Arlo Smart, our AI-based subscription service. Smart notifications enhanced by secure, simple access via the Arlo App, enable users to  quickly and easily live stream their front entryway, respond to delivery personnel, greet guests and even contact emergency services when needed.”  

Direct-to-mobile video calls, clear, two-way audio and pre-recorded quick-reply messages all enable convenient, in-the-moment communication with visitors. Traditionally, video doorbells require users to take multiple steps to view and respond to guests once receiving a notification, causing delays where a user could easily miss their visitor. The Arlo Essential Video Doorbell Wire-Free solves this problem by sending a live, HD video call right to the user’s smartphone once the doorbell is pressed, enabling them to quickly take action by deploying a response.

Features of the all-new Arlo Essential Video Doorbell Wire-Free include:

  • 180° Viewing Angle: Optimized for the front door with a 1:1 aspect ratio so you can see a person from head to toe or a package on the ground
  • Direct-to-Mobile Video Call: Calls your phone directly so you never miss a visitor
  • Multiple Powering Options: Install without wires using the rechargeable battery1, or hardwire to existing wiring for continuous charging2
  • Motion Detection and Alerts: Receive alerts when motion is detected

  • Angle Mount:
    Easily adjust viewing angle to fully and clearly see visitors
  • 2-Way Audio: Hear what matters with clear, noise-cancelling audio
  • More Ways to Answer: Quick Reply Messages enable users to play pre-recorded messages for instant response to guests
  • Visitor Messaging: Guests can leave you a voice message if you’re unable to answer the door, and you can listen remotely at your convenience
  • HD Video with HDR: Capture vivid detail in bright and dark areas with HDR
  • Night Vision: See who’s at your door at night, even without a light on
  • Weather Resistant: Designed to withstand heat, cold, rain or sun
  • Platform Compatibility: Works with Alexa, Google Assistant and IFTTT for easy interaction, automation, and control
  • Direct to WiFi: Connects directly to WiFi for simple setup allowing it to function as a standalone home security solution without the need for a separate base station
  • Built-In Smart Siren: Trigger your siren automatically or manually from the Arlo app during an event
  • Silent Mode: Temporarily disable incoming calls, Arlo Chime melodies, and/or traditional chime rings
  • Notifications that Matter: Get alerts when your Essential Video Doorbell Wire-Free spots people, vehicles, animals or a package with Arlo Smart via an included three-month trial with rolling 30-day cloud recordings

The purchase of an Arlo Essential Video Doorbell Wire-Free unlocks a complimentary three-month trial to Arlo’s AI subscription-based service, Arlo Smart. Users will receive access to 30-days of rolling HD video recordings to store and view video clips. Notification settings can be adjusted, enabling Arlo Smart subscribers to fully customize their experience to spot people, vehicles, animals or packages3. Arlo Smart’s e911 feature provides access to emergency services local to the camera’s location for quick action in emergency situations4. Controlled entirely through the Arlo app, users can easily view live streams and recordings, adjust their camera settings or access cloud recordings.

For more information on the full range of Arlo smart home security products and services, visit www.arlo.com.

About Arlo Technologies, Inc.
Arlo is the award-winning, industry leader that is transforming the way people experience the connected lifestyle. Arlo’s deep expertise in product design, wireless connectivity, cloud infrastructure and cutting-edge AI capabilities focuses on delivering a seamless, smart home experience for Arlo users that is easy to setup and interact with every day. The company’s cloud-based platform provides users with visibility, insight and a powerful means to help protect and connect in real-time with the people and things that matter most, from any location with a Wi-Fi or a cellular connection. To date, Arlo has launched several categories of award-winning smart connected devices, including wire-free smart Wi-Fi and LTE-enabled security cameras, audio and video doorbells, and floodlight. 

With a mission to bring users peace of mind, Arlo is as passionate about protecting user privacy as it is about safeguarding homes and families. Arlo is committed to supporting industry standards for data protection designed to keep users’ personal information private and in their control. Arlo doesn’t monetize personal data, provides enhanced controls for user data, supports privacy legislation, keeps user data safely secure, and puts security at the forefront of company culture.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. The words “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words are used to identify such forward-looking statements. However, the absence of these words does not mean that the statements are not forward-looking. The forward-looking statements represent Arlo Technologies, Inc.’s expectations or beliefs concerning future events based on information available at the time such statements were made and include statements regarding Arlo Essential Video Doorbell Wire-Free, Arlo Smart, and future Arlo products. These statements are based on management’s current expectations and are subject to certain risks and uncertainties, including the following: future demand for the Company’s products may be lower than anticipated; consumers may choose not to adopt the Company’s new product offerings or adopt competing products; and product performance may be adversely affected by real world operating conditions. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Therefore, actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. Further information on potential risk factors that could affect Arlo and its business are detailed in the Company’s periodic filings with the Securities and Exchange Commission, including, but not limited to, those risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Given these circumstances, you should not place undue reliance on these forward-looking statements. Arlo undertakes no obligation to release publicly any revisions to any forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

1Rechargeable battery lasts up to six months on one charge. Applies only to battery powered installation. Based on usage of 4000 seconds motion streaming per month, 30 seconds per two-way call daily, and day/night event splits 2:1. Will vary with device settings, use, activity captured and environmental factors.
2 If choosing to hardwire, users will need existing electrical/doorbell wiring with voltage between 8V AC and 24V AC.
3 Personalized alerts made available through the complimentary three-month Arlo Smart trial subscription
4 Available to customers in the United States only.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/all-new-arlo-essential-video-doorbell-wire-free-now-available-301187101.html

SOURCE Arlo Technologies, Inc.

Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer

Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer

— Research collaboration focused on the discovery of novel bispecific antibodies directed toward the CD28 co-stimulatory receptor and an undisclosed prostate tumor target —

— Xencor receives $50 million upfront payment and is eligible to receive potential milestone payments and a royalty on net sales from commercialized medicines —

— Each company receives the right to conduct directed non-registrational clinical studies in prostate cancer, combining agents in its respective pipeline with select agents from the other’s portfolio —

MONROVIA, Calif.–(BUSINESS WIRE)–
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced it has entered into a research collaboration and license agreement with Janssen Biotech, Inc. (Janssen). The research and license agreement is focused on the discovery of XmAb® bispecific antibodies against CD28, an immune co-stimulatory receptor on T cells, and an undisclosed prostate tumor target, for the potential treatment of patients with prostate cancer. Additionally, Xencor has a right to access select, predefined agents from Janssen’s portfolio of clinical-stage drug candidates and commercialized medicines to evaluate potential combination therapies in prostate cancer with agents in its own pipeline in non-registrational clinical studies. Janssen has the same right with Xencor’s portfolio of clinical-stage drug candidates to evaluate potential combination therapies in prostate cancer, as well.

“Our XmAb bispecific Fc domains enable the creation of a wide range of multi-specific antibody and protein structures, such as bispecific antibodies in our new CD28 platform. These antibodies can co-stimulate T cells in a tumor-target dependent manner and can synergize with both checkpoint inhibitor therapies and other tumor-targeted agents, like CD3 bispecific antibodies, in order to enhance anti-tumor activity,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. “In addition, the ability to study combinations of therapies from both companies’ prostate cancer portfolios leverages Xencor’s broad clinical pipeline and the leading prostate cancer therapeutics portfolio at Janssen. This collaboration with Janssen expands the use of our CD28 platform and complements our first wholly owned internal candidate, a B7-H3 x CD28 bispecific antibody designed to treat a range of solid tumors, which is currently advancing through preclinical development.”

Under the terms of the agreement, Xencor will apply its XmAb bispecific Fc technology to create and characterize XmAb CD28 bispecific antibody candidates against the tumor target specified by Janssen. Preclinical activities and all clinical development, regulatory and commercial activities will be conducted by Janssen, which has exclusive worldwide rights to develop and commercialize the novel drug candidates. Xencor will receive an upfront payment of $50 million and will be eligible to receive development, regulatory and sales milestone payments and high-single digit to low-double digit percent royalties on net sales.

Upon clinical proof of concept for a bispecific antibody candidate, Xencor has the right to opt-in to fund 20 percent of development costs and to perform up to 30 percent of the detailing efforts in the United States; Xencor would be eligible for milestone payments and low-double digit to mid-teen percent royalties on net sales.

The agreement is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act, and closing is expected to occur by year end.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 18 candidates engineered with Xencor’s XmAb® technology are in clinical development internally and with partners. Xencor’s XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of applicable securities laws, including, but not limited to, the quotations from Xencor’s president and chief executive officer and any expectations relating to Xencor’s financial expectations and business, the timing and success of clinical trials, future product candidates, Xencor’s research and development programs, partnering efforts and capital requirements. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks described in Xencor’s public securities filings. For a discussion of these and other factors, please refer to Xencor’s annual report on Form 10-K for the year ended December 31, 2019 as well as Xencor’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements are based on Xencor’s current information and belief as well as assumptions made by Xencor. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Xencor undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

Charles Liles

[email protected]

Media Contact

Jason I. Spark

Canale Communications

619-849-6005

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo
Logo

WSGF – P2P Short-Term Rental Investment Firm Vaycaychella Adds New Caribbean 3 Unit Property To Portfolio Available On Airbnb

PR Newswire

DALLAS, Dec. 7, 2020 /PRNewswire/ — World Series of Golf, Inc. (USOTC: WSGF) (“WSGF”), through its sharing economy technology subsidiary serving the short-term rental market, Vaycaychella, today announced closing on the acquisition of a historic building in Old San Juan, Puerto Rico.  The property has three units which will be made available for short-term rentals through Airbnb, VRBO and Booking.com after the property is refurbished.

WSGF is in the process of changing its corporate name in conjunction with the acquisition of Vaycaychella earlier this year.

“We here at Vaycaychella are enthusiastic participants in the sharing economy specifically tied to the short-term rental sector of the sharing economy currently spotlighted by the pending Airbnb IPO,” said William “Bill” Justice, CEO of Vayaychella.  “We have built a pilot ecosystem model connecting investors with individuals seeking the development and operation of short-term rental properties.  Over the past three years we have partnered with vacation property operators in the Caribbean to build a portfolio of properties with an estimated value over $10 million.  Now, we are excited to scale that model with the introduction of a peer-to-peer application, also known as a P2P app, automating the connection between investors and prospective short-term rental property owners and operators.”

To learn more about Vaycaychella’s strategy to capitalize its own growth in conjunction with the Airbnb IPO, see CEO William “Bill” Justice’s letter to investors published Friday, December 4th.

Vaycaychella recently announced inviting individuals to sign up as Beta Users to begin testing the Vaycaychella P2P Investment App.

Vaycaychella’s vision is to empower existing and would-be short-term rental property owners to access investment capital for property acquisitions and improvements financed outside the conventional lending and investment market.

Through Vaycaychella’s P2P app, small business lenders and investors, and even private individuals can connect with entrepreneurial short-term property rental operators to access real estate leveraged investment opportunities not usually available through conventional brokers and agents.

Likewise, entrepreneurial short-term property rental operators now have access to a wider variety of investment options than ordinarily available through conventional channels.

Vaycaychella has built a pilot client base serving a Caribbean based vacation property owner with 10 beachfront community vacation homes currently under management.   Vaycaychella has financed the property owner to acquire and refurbish the 10 premium properties which serve as collateral on Vaycaychella’s investment.

Last week, Vaycaychella announced adding a boutique hotel in the Caribbean to its portfolio of short-term rental properties available on sharing economy apps like Airbnb, VRBO and Booking.com.  Sharing economy apps are taking an increasing share of the $32 billionCaribbean vacation market.

Today, Vaycaychella adds the property in Puerto Rico to its portfolio.  Once refurbishment is completed, the building will include three short-term rental units available on sharing economy apps like Airbnb, VRBO and Booking.com. 

To learn more and keep up with the latest updates, visit https://www.vaycaychella.com/. At the company website, you will find a blog with frequent industry publications on the short-term rental market in general, as well as entries specific to Vaycaychella.

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

WSGF Contact:
William “Bill” Justice
[email protected]
(800) 871-0376

Cision View original content:http://www.prnewswire.com/news-releases/wsgf–p2p-short-term-rental-investment-firm-vaycaychella-adds-new-caribbean-3-unit-property-to-portfolio-available-on-airbnb-301186874.html

SOURCE World Series of Golf, Inc.

Pingtan Marine Enterprise to Hold Annual General Meeting of Members on December 23, 2020

PR Newswire

FUZHOU, China, Dec. 7, 2020 /PRNewswire/ — Pingtan Marine Enterprise Ltd. (Nasdaq: PME), (“Pingtan” or the “Company”), today announced that the Company will hold its Annual General Meeting of Members (“AGM”) on December 23, 2020, at 10:00 a.m. China Standard Time. The meeting will be held at 18 Floor, Zhongshan Building A, No. 154 Hudong Road, Fuzhou, Fujian, People’s Republic of China.

At the meeting, the following proposals will be submitted to shareholders to vote upon, as fully described in the proxy statement filed with the U.S. Securities and Exchange Commission and first made available to shareholders on November 12, 2020:

  • The election of one Class B director to the Board of Directors and to serve for a three-year term to expire at the 2023 annual general meeting or until his successor is duly elected and qualified; 
  • The approval, on a non-binding advisory basis, of the compensation of the Company’s executive officers;
  • The consideration, on a non-binding advisory basis, of the frequency on future advisory votes on executive compensation; and
  • The ratification of the appointment of BDO China Shu Lun Pan Certified Public Accountants LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2020;

Only shareholders of record of the Company’s ordinary shares at the close of business on November 9, 2020 will be entitled to receive notice of and attend the AGM and any adjournment or postponement thereof.

About Pingtan

Pingtan is a fishing company engaging in ocean fishing through its subsidiary, Fujian Provincial Pingtan County Ocean Fishing Group Co., Ltd., or Pingtan Fishing.

CONTACT:
LiMing Yung (Michael)
Chief Financial Officer
Pingtan Marine Enterprise Ltd.
Tel: +86 591 87271753
[email protected] 

Maggie Li

Investor Relations Manager
Pingtan Marine Enterprise Ltd.
Tel: +86 591 8727 1753
[email protected]

INVESTOR RELATIONS
PureRock Communications Limited
[email protected] 

 

Cision View original content:http://www.prnewswire.com/news-releases/pingtan-marine-enterprise-to-hold-annual-general-meeting-of-members-on-december-23-2020-301187264.html

SOURCE Pingtan Marine Enterprise Ltd.

Dolly Varden Silver Acquires Strategic Surface Rights on Tidewater at Alice Arm, BC

PR Newswire

VANCOUVER, BC, Dec. 7, 2020 /PRNewswire/ – Dolly Varden Silver Corporation (“Dolly Varden” or the “Company“) (TSXV: DV) (OTC:DOLLF), is pleased to announce the acquisition of surface rights and fee simple lands within the community of Alice Arm located on the Pacific Ocean in Northwest BC, in support of exploration infrastructure. The town of Alice Arm was originally developed in the early 1900’s to support silver mining in the area.

The surface rights acquired include: the lands where the exploration camp, offices, logging and sampling facilities, as well as core storage areas are currently located. In addition, one parcel is located at waterfront with the potential to construct deep water loading facilities. The total package had been previously leased annually by the Company from private owners.

“Acquiring the title to these surface lands secures the future of the exploration camp and geological facilities as well as establishes the asset of having strategically located building sites for future infrastructure needs”, states Shawn Khunkhun, President and CEO.

The transaction involves a payment of Cnd$150,000 in cash and Cnd$150,000 in fully paid common shares of the company issued at a deemed price per share equal to the 10-day simple average of the closing price of the shares on the TSX Venture Exchange (“TSXV“) immediately preceding the issue date. The transaction is subject to final approval of the TSXV. The Company currently has title to the underlying mineral leases on the larger lots within the land package but does not intend to conduct exploration on them.

Qualified Person

Rob van Egmond, P.Geo, Chief Geologist for Dolly Varden Silver, is the “Qualified Person” as defined by NI43-101. He has reviewed, validated and approved the information contained in this news release.

About Dolly Varden Silver Corporation

Dolly Varden Silver Corporation is a mineral exploration company focused on exploration in northwestern British Columbia. Dolly Varden has two projects, the namesake Dolly Varden silver property and the nearby Big Bulk copper-gold property. The Dolly Varden property is considered to be highly prospective for hosting high-grade precious metal deposits, since it comprises the same structural and stratigraphic setting that host numerous other high-grade deposits (Eskay Creek, Brucejack). The Big Bulk property is prospective for porphyry and skarn style copper and gold mineralization similar to other such deposits in the region (Red Mountain, KSM, Red Chris).

Forward Looking Statements

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of Dolly Varden to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Forward looking statements or information relates to, among other things, final approval of the TSXV, interpretation of the nature of the mineralization at the project and that that the mineralization on the project is similar to Eskay and Brucejack, results of the mineral resource estimate on the project, the potential to grow the project, the potential to expand the mineralization, the planning for further exploration work, the ability to de-risk the potential exploration targets, and our beliefs about the unexplored portion of the property. These forward-looking statements are based on management’s current expectations and beliefs but given the uncertainties, assumptions and risks, readers are cautioned not to place undue reliance on such forward-looking statements or information. The Company disclaims any obligation to update, or to publicly announce, any such statements, events or developments except as required by law.

For additional information on risks and uncertainties, see the Company’s most recently filed annual management discussion & analysis (“MD&A”), which is available on SEDAR at www.sedar.com. The risk factors identified in the MD&A are not intended to represent a complete list of factors that could affect the Company.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this news release.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/dolly-varden-silver-acquires-strategic-surface-rights-on-tidewater-at-alice-arm-bc-301187160.html

SOURCE Dolly Varden Silver Corp.

Seqirus Presents New Late-Breaking Data at ESWI 2020 Highlighting Benefits of MF59®-Adjuvanted Seasonal Influenza Vaccine

PR Newswire

SUMMIT, N.J., Dec. 7, 2020 /PRNewswire/ — Seqirus, a global leader in influenza prevention and influenza pandemic response, today announced new late-breaking data from a systematic review and meta-analysis presented at the European Scientific Working Group on Influenza (ESWI) virtual conference confirming the benefit of an MF59®-adjuvanted trivalent seasonal influenza vaccine (aTIV) for adults 65 years and older.1 Results indicate that relative vaccine effectiveness (rVE) favored aTIV over non-adjuvanted standard dose quadrivalent and trivalent influenza vaccines in averting influenza-related medical encounters.1 aTIV was comparable to a high-dose TIV for the same outcome.1

Influenza causes significant morbidity and mortality in adults 65 years and older, as demonstrated by higher hospitalization and death rates in most recent years, compared with young, healthy adults.2 Seasonal influenza vaccine effectiveness may be impacted by age-related immune decline in this population, which can result in reduced immune response to standard influenza vaccines.3,4 The MF59® adjuvant included in aTIV is designed to enhance the immune response to the influenza strains contained in the vaccine in adults 65 years and older.5,6,7

The data presented at ESWI 2020 comes from a systematic review and meta-analysis of 16 real-world studies over a period of 20 years that evaluated the effectiveness of vaccination with aTIV relative to non-adjuvanted egg-based influenza vaccines or no vaccine in adults 65 years or older.1

“To have results from a systematic review and meta-analysis provides an additional level of evidence for the benefit of adjuvanted influenza vaccines in older adults who face age-related immune decline,” said Brenda L. Coleman, RN, PhD, Infectious Disease Epidemiologist, Sinai Health System, Toronto; Assistant Professor, Dalla Lana School of Public Health, University of Toronto.

The MF59® adjuvant is designed to enhance the immune response by increasing the magnitude and persistence of antibody response and creating more diverse, cross-reactive antibodies.6,7,8 This may be important when there is a mismatch between the virus strains included in the vaccine and the strains circulating in the community.7,9,10,11,12,13

“Adults age 65 years and older are at higher risk for complications from seasonal influenza. At Seqirus, we’re focused on utilizing advanced technology like the MF59® adjuvant to potentially offer better protection against influenza for those most vulnerable, like adults in this age group,” said Gregg Sylvester, MD, Chief Medical Officer at Seqirus. “With both COVID-19 and influenza circulating in the Northern Hemisphere this season, it’s critical that as many people as possible receive an influenza vaccine to protect against the flu, and therefore help to keep pressure off health systems during the continued pandemic.”

This MF59®-adjuvanted seasonal influenza vaccine has an extensive clinical legacy, with 155+ million doses distributed over 20+ years* and licensure in 30 countries.14 The quadrivalent formulation of the MF59®-adjuvanted influenza vaccine, which adds an additional B strain to the trivalent formulation, was approved by the U.S. Food and Drug Administration (FDA) in February 2020 and in Europe in March 2020 and is available for the 2020/21 influenza season.15

*Doses distributed globally as of November 2020, including both trivalent and quadrivalent formulations.

About the Study
This abstract is a systematic review and meta-analysis on real-world studies that evaluated the effectiveness of vaccination with MF59®-adjuvanted trivalent seasonal influenza vaccine (aTIV) relative to vaccination with non-adjuvanted egg-based influenza vaccines or no vaccine in adults 65 years of age and above.1

The systematic review using Cochrane methods included 21 studies after screening 4,374 peer-reviewed journal articles published between January 1, 1997 and July 15, 2020.1 Of these 21 studies, 16 of these were considered sufficiently comparable to include in one of the meta-analyses.1 Pooled relative vaccine effectiveness (rVE) estimates are presented with their 95% confidence intervals.1

Meta-analysis of studies found that aTIV was effective in reducing general practice visits and hospital admissions (absolute VE).1 Pooled estimates of rVE favored aTIV over non-adjuvanted standard dose quadrivalent and trivalent influenza vaccines in averting influenza-related medical encounters.1 aTIV was comparable to high-dose TIV in averting influenza-related medical encounters.1 Although substantial heterogeneity was observed, estimates for rVE were consistently in favor of aTIV over the standard-dose non-adjuvanted vaccines, with the exception of one study.1

About Seasonal Influenza 
Influenza is a common, contagious seasonal respiratory disease that may cause severe illness and life-threatening complications in some people.16 Influenza can lead to clinical symptoms varying from mild to moderate respiratory illness to severe complications, hospitalization and in some cases, death.16 The Centers for Disease Control and Prevention (CDC) recommends annual vaccination for individuals aged 6 months and older, who do not have any contraindications.17 Because transmission of influenza viruses to others may occur one day before symptoms develop and up to 5 to 7 days after becoming sick, the disease can be easily transmitted to others.16 Preliminary estimates from the CDC report that from October 1, 2019, through April 4, 2020, there were an estimated 410,000 to 740,000 influenza-related hospitalizations in the U.S.18 Since it takes about two weeks after vaccination for antibodies to develop in the body that help protect against influenza virus infection, it is recommended that people get vaccinated before influenza begins spreading in their community.16 The CDC recommends that people get vaccinated by the end of October.19 However, getting vaccinated too early (for example, in July or August), can be associated with reduced protection against influenza infection later in the flu season.19

About Seqirus
Seqirus is part of CSL Limited (ASX: CSL). As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.

About CSL
CSL (ASX: CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus – provides life-saving products to more than 100 countries and employs more than 27,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information about CSL Limited, visit www.csl.com.

For more information visit www.seqirus.com and www.csl.com.

Intended Audience
This press release is issued from Seqirus USA Inc. in Summit, New Jersey, USA and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved Seqirus products may vary from country to country. Please consult your local regulatory authority on the approval status of Seqirus products.

Forward-Looking Statements
This press release may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

MF59® is a registered trademark of Seqirus UK Limited or its affiliates.

US/GLB/FLUD/1120/0036

MEDIA CONTACT

Polina Miklush  
+1 (908) 608-7170
[email protected]

1Effectiveness of the MF59® -Adjuvanted Trivalent Seasonal Influenza Vaccine Among Adults Aged 65 or Older, a Systematic Review and Meta-analysis. Presented at ESWI 2020.

2Centers for Disease Control and Prevention (CDC). (2019). People 65 years and Older & Influenza. Retrieved from: https://www.cdc.gov/flu/highrisk/65over.htm. Accessed November 2020.

3Monto AS, Ansaldi F, Aspinall R, et al. (2009). Influenza control in the 21st century: Optimizing protection of older adults. Vaccine. 2009;27(37):5043-5053.

4McElhaney JE, Verschoor CP, Andrew MK, et al. (2020). The immune response to influenza in older humans: beyond immune senescence. BMC.

5Frey SE, Aplasca-De Los Reyes MR, Reynales H, et al. (2014). Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine. 2014;32:5027-5034.

6O’Hagan DT, Ott GS, Nest GV, et al. (2013). The history of MF59® adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines. 2013;12(1):13-30.

7Banzhoff A, Pellegrini M, Del Giudice G, et al. (2008). MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respir Viruses. 2008;2(6):243-24.

8O’Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59—an innately attractive adjuvant formulation. Vaccine. 2012;30(29):4341-4348.

9Del Giudice G, Hilbert AK, Bugarini R, et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine. 2006:24(16):3063-3065.

10Ansaldi F, Bacilieri S, Durando P, et al. Cross-protection by MF59™-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine. 2008;26(12):1525-1529.

11Ansaldi F, Zancolli M, Durando P, et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine. 2010;28(25):4123-4129.

12Frey SE, Reyes MR, Reynales H, et al. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine. 2014;32(39):5027-5034.

13Kavian N, Hachim A, Li APY, et al. Assessment of enhanced influenza vaccination finds that Fluad conveys an advantage in mice and older adults. Clin Transl Immunology. 2020;9(2):e1107.

14Data on file. Seqirus Inc; 2019.

15FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) [package insert]. Holly Springs, NC: Seqirus Inc; 2020.

16CDC. (2019). Key Facts about Influenza (Flu). Retrieved from: https://www.cdc.gov/flu/about/keyfacts.htm.  Accessed November 2020.

17CDC. (2020). Key Facts About Seasonal Flu Vaccine. Retrieved from: https://www.cdc.gov/flu/prevent/keyfacts.htm. Accessed November 2020.

18CDC. (2020). 2019-2020 U.S. Flu season: Preliminary burden estimates. Retrieved from: https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm. Accessed November 2020.

19CDC. (2020). Who Needs a Flu Vaccine and When. Retrieved from: https://www.cdc.gov/flu/prevent/vaccinations.htm. Accessed November 2020.

Cision View original content:http://www.prnewswire.com/news-releases/seqirus-presents-new-late-breaking-data-at-eswi-2020-highlighting-benefits-of-mf59-adjuvanted-seasonal-influenza-vaccine-301187248.html

SOURCE Seqirus

Sesame Workshop and Viatris Inc. Launch Global Resources to Help Children and Caregivers Manage Social and Emotional Needs During Upcoming Holiday Season and Beyond

New animations and materials featuring the Sesame Street Muppets address key emotions that families are feeling during the COVID-19 pandemic

PR Newswire

NEW YORK, Dec. 7, 2020 /PRNewswire/ — Ahead of a holiday season that will look dramatically different this year for many children and families, Sesame Workshop and Viatris Inc. (NASDAQ: VTRS) are launching new resources to support the social and emotional needs of families across generations and around the world during the COVID-19 pandemic. Today’s release of materials on SesameStreet.org/caring in English, Spanish, Hindi, and Portuguese is designed to help young children talk through and name big feelings like stress and fear, encourage positive caregiving strategies and routines, and help families find ways to celebrate together when far apart. Made possible by the generous support of Viatris, the new global resources will reach families on 6 continents.

“We know children and families everywhere are struggling as the COVID-19 pandemic continues. Together with Viatris, we are offering families strategies to cope with today’s challenges and foster emotional wellbeing long into the future,” said Sherrie Westin, President of Social Impact and Philanthropy, Sesame Workshop. “As we head into the holidays with so many routines upended, we want to help children and their caregivers manage big feelings and spend quality time with each other, even when apart.”

Starting this week, new animations and activities will launch on a rolling basis in the U.S., India, South Africa, and Latin America, with select content available in Europe and Australia. In one video, Grover and his mom decide to make his Grandmother’s special family soup over videochat when they can’t be together for their holiday celebration. In additional videos, Elmo and his mom talk about big feelings and Elmo’s dad helps him name and cope with the feeling of fear of getting sick. Additional topics released on a rolling basis will include keeping routines, spending special time together, and learning about persistence.

“Our work with Sesame Workshop stems from our mission to empower people worldwide to live healthier at every stage of life,” said Lara Ramsburg, Head of Corporate Affairs for Viatris. “From young children to parents, grandparents, and other caregivers, we hope these new resources will be of value to anyone who has experienced the emotional impact of the pandemic on their families. As we begin our journey as Viatris, we’re committed to supporting social impact initiatives and partnerships that have the potential to have a lasting, positive impact on patients, families and communities worldwide. We’re pleased to collaborate with Sesame Workshop, who has a long history of making a difference in the lives of children around the world.”

Viatris, a new kind of global healthcare company, is committed to doing its part in support of public health needs amid the COVID-19 pandemic. In addition to the generous support to make these new resources possible, Viatris will share the resources with its global workforce of approximately 45,000.

The resources launched today as part of Sesame Workshop’s Caring for Each Other initiative, which was created in response to the uncertainty facing families during the COVID-19 pandemic and has reached families in more than 100 countries and 41 languages. SesameStreet.org/caringis regularly updated to meet the needs of families as the situation evolves, with resources designed to help parents provide comfort and manage anxiety, as well as help with creating routines, fostering playful learning at home and staying physically and mentally healthy. Resources will also be distributed through a wide range of national and community providers as part of Sesame Street in Communities, Sesame Workshop’s program to support children and families.

About Sesame Workshop

Sesame Workshop is the nonprofit educational organization behind Sesame Street, the pioneering television show that has been reaching and teaching children since 1969. Today, Sesame Workshop is an innovative force for change, with a mission to help kids everywhere grow smarter, stronger, and kinder. We’re present in more than 150 countries, serving vulnerable children through a wide range of media, formal education, and philanthropically funded social impact programs, each grounded in rigorous research and tailored to the needs and cultures of the communities we serve. For more information, please visit www.sesameworkshop.org.

About Viatris
Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway™.  Formed in November 2020 through the combination of Mylan and Pfizer’s Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 45,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/sesame-workshop-and-viatris-inc-launch-global-resources-to-help-children-and-caregivers-manage-social-and-emotional-needs-during-upcoming-holiday-season-and-beyond-301186981.html

SOURCE Viatris Inc.

PriceSmart Announces November Net Merchandise Sales; Opening of Eighth Warehouse Club in Colombia; and Earnings Release and Conference Call Details for the First Quarter of Fiscal 2021

PR Newswire

SAN DIEGO, Dec. 7, 2020 /PRNewswire/ — PriceSmart, Inc. (NASDAQ: PSMT) today announced that for the month of November 2020, net merchandise sales increased 7.9% to $300.0 million from $278.1 million in November a year earlier. Foreign currency exchange fluctuations impacted net merchandise sales negatively by 3.4%, or $9.8 million, versus the same one-month period in the prior year. There were 46 warehouse clubs in operation at the end of November 2020 and 45 warehouse clubs in operation at the end of November 2019.

For the five weeks ended November 29, 2020, comparable net merchandise sales for the 43 warehouse clubs open at least 13 ½ full months increased 5.6% when compared to the same period last year. Foreign currency exchange rate fluctuations impacted comparable net merchandise sales negatively by 3.5%, or $11.0 million, versus the same period in the prior year.


New Club Opening:

PriceSmart, Inc. also held the grand opening of its new warehouse club in Bogotá, Colombia on December 4, 2020, bringing to 47 the total number of warehouse clubs in operation. This warehouse club is located within the Usaquén locality, on the northern side of Bogotá, Colombia. The Usaquén Club is PriceSmart’s eighth warehouse club in Colombia and the third in the greater metropolitan area of Bogotá.

Sherry S. Bahrambeygui, Chief Executive Officer, commented:

“Our strong start to fiscal year 2021 has been fueled by many new practices and improvements that we planned for and set into motion during our prior fiscal year. In November, we experienced continued growth in net merchandise sales and strong comparable sales growth. Of note, last year’s Smart Weekend event in the Caribbean was expanded this year to a Smart Week program across all of our markets. Our digital marketing efforts have been strengthened, and net merchandise sales increased across multiple categories in most markets, especially in non-food categories such as electronics.

Our Click & Go™ service, including curbside pickup and delivery, contributed approximately 2.9% of total net merchandise sales for the month of November. The demand for delivery through our Click &Go™ service, which is now available in all of our markets, has been increasing and represents a growing proportion of total Click & Go™ sales. Developing greater efficiencies remains a priority especially within these new sales channels.  We believe that Click & Go™ curbside and delivery services will remain important alternative shopping methods and provide increased value for our Members by enabling them to leverage their membership across multiple shopping platforms. We also see value in the insights gained by communicating with our Members through a variety of our online channels.

Last Friday, we celebrated the grand opening of the new Usaquén Club, which is strategically located in the heart of a densely populated area of Bogotá, and is poised to drive sales growth, provide greater convenience for our Members, and strengthen our presence in this important market that has significant potential. This new club is not terribly distant from our two other clubs in the greater metropolitan area of Bogotá. Therefore, we anticipate some transfer of sales from those existing clubs to the new club, which may adversely impact our comparable net merchandise sales in the near term.  However, this location provides opportunity for incremental Membership and sales growth, given the demographics and appeal of our uniquely curated selection of goods and services at great values.

Although pandemic-related restrictions eased somewhat in November, we remain acutely focused on monitoring and responding to changes that could develop in upcoming months. The operating results we experience today are attributable to a combination of improvements that were being developed pre-COVID, the new capabilities that were launched during COVID, and our team’s ability to execute quickly to better serve our Members’ needs in a dynamic environment. We are well positioned to continue to convert challenges into opportunities for additional growth while enhancing our Members’ shopping experience.”

Fiscal year to date, which includes the three months ended November 30, 2020, net merchandise sales increased 7.7% to $838.4 million from $778.7 million for the three months ended November 30, 2019. Foreign currency exchange rate fluctuations impacted net merchandise sales negatively by 3.5% or $27.5 million versus the same three-month period in the prior year.

For the 13-week period ended November 29, 2020, comparable net merchandise sales increased 3.6% compared to the same 13-week period a year ago. Foreign currency exchange rate fluctuations impacted comparable net merchandise sales negatively by 3.5% or $27.0 million versus the same prior year period.


First Quarter 2021 Earnings Announcement Details:

PriceSmart plans to release first quarter fiscal year 2021 financial results on Thursday, January 7, 2021, after the market closes. PriceSmart management will host a conference call at 12:00 p.m. Eastern time (9:00 a.m. Pacific time) on Friday, January 8, 2021, to discuss the financial results. Individuals interested in participating in the conference call may do so by dialing (855) 209-8211 toll free, or (412) 317-5214 for international callers and asking to join the PriceSmart, Inc. call. A digital replay will be available through January 15, 2021, following the conclusion of the call by dialing (877) 344-7529 for domestic callers, or (412) 317-0088 for international callers, and entering replay passcode 10149960.


About PriceSmart

PriceSmart, headquartered in San Diego, owns and operates U.S.-style membership shopping warehouse clubs in Latin America and the Caribbean, selling high quality merchandise and services at low prices to PriceSmart Members. PriceSmart operates 47 warehouse clubs in 12 countries and one U.S. territory (eight in Costa Rica and Colombia; seven in Panama; five in the Dominican Republic, four in Trinidad and Guatemala; three in Honduras; two each in El Salvador and Nicaragua; and one each in Aruba, Barbados, Jamaica and the United States Virgin Islands).

The Company reports comparable net merchandise sales on a “same week” basis with 13 weeks in each quarter beginning on a Monday and ending on a Sunday. The periods are established at the beginning of the fiscal year to provide as close a match as possible to the calendar month and quarter that is used for financial reporting purposes.  This approach equalizes the number of weekend days and weekdays in each period for an improved sales comparison, as the Company experiences higher merchandise club sales on the weekends. Each of the warehouse clubs used in the calculations was open for at least 13 ½ calendar months before its results for the current period were compared with its results for the prior period.

The term “currency exchange rates” refers to the currency exchange rates the Company uses to convert net merchandise and comparable net merchandise sales for all countries where the functional currency is not the U.S. dollar into U.S. dollars. The Company calculates the effect of changes in currency exchange rates as the difference between current period activities translated using the current period’s currency exchange rates and the comparable prior year period’s currency exchange rates. The Company believes the disclosure of the effects of currency exchange rate fluctuations on the Company’s results permits investors to understand better the Company’s underlying performance.

This press release may contain forward-looking statements concerning the Company’s anticipated future revenues and earnings, adequacy of future cash flows, omni-channel initiatives, proposed warehouse club openings, the Company’s performance relative to competitors, the outcome of tax proceedings and related matters. These forward-looking statements include, but are not limited to, statements containing the words “expect,” “believe,” “will,” “may,” “should,” “project,” “estimate,” “anticipated,” “scheduled,” and like expressions, and the negative thereof. These statements are subject to risks and uncertainties that could cause actual results to differ materially including, but not limited to: adverse changes in economic conditions in the Company’s markets, natural disasters, compliance risks, volatility in currency exchange rates, competition, consumer and small business spending patterns, political instability, increased costs associated with the integration of online commerce with our traditional business, whether the Company can successfully execute strategic initiatives, breaches of security or privacy of member or business information, cost increases from product and service providers, interruption of supply chains, member or business information, cost increases from product and service providers, interruption of supply chains, COVID-19 related factors and challenges, including among others, the duration of the pandemic, the unknown long-term economic impact, the impact of government policies and restrictions that have limited access for our Members, and shifts in demand away from discretionary or higher priced products to lower priced products, exposure to product liability claims and product recalls, recoverability of moneys owed to PriceSmart from governments, and other important factors discussed in the Risk Factors section of the Company’s most recent Annual Report on Form 10-K, and other factors discussed from time to time in other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Forward-looking statements speak only as of the date that they are made, and the Company does not undertake to update them, except as required by law.

For further information, please contact Michael L. McCleary, EVP, Chief Financial Officer and Principal Accounting Officer (858) 404-8826 or send an email to [email protected].

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/pricesmart-announces-november-net-merchandise-sales-opening-of-eighth-warehouse-club-in-colombia-and-earnings-release-and-conference-call-details-for-the-first-quarter-of-fiscal-2021-301186948.html

SOURCE PriceSmart, Inc.